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Background: BRCA mutations are the main known hereditary factor for ovarian cancer. Notably, emerging
evidence indicates that the glucocorticoid receptor (GR) has drawn considerable interest in ovarian cancer
development. However, dynamic cross-talk between BRCA1 and GR signaling pathways are poorly understood.
Methods: The regulatory effects of BRCA on GR were assessed in 146 serous ovarian cancer patients (28 pairs of
BRCA1-mutated or not, 23 pairs of BRCA2-mutated or not, and 22 pairs with hypermethylated BRCA1 promoter or
not). BRCA1 promoter methylation was analyzed by bisulfite sequencing using primers flanking the core promoter
region. Expression levels of BRCA1 and GR were assessed by immunohistochemistry and real-time PCR. Regression
analysis was used to examine the possible relationship between BRCA1 and GR expression levels. The knockdown
and overexpression of BRCA1 were achieved using a lentiviral vector in 293 T cells, SKOV3 ovarian cancer cells, and
primary non-mutated and BRCA1-mutated ovarian cancer cells.
Results: GR expression levels were unchanged in non-BRCA1-mutated, non-BRCA2-mutated and BRCA2-mutated
ovarian cancer compared to their normal tissues; BRCA1 repression (BRCA1 mutation or BRCA1 promoter
hypermethylation) ovarian cancer showed decreased GR levels compared to normal tissue; there was a positive
correlation between BRCA1 and GR expression in human ovarian cancer specimens; BRCA1 knockdown was
effective at inhibiting GR expression, and overexpression of BRCA1 induces an increase in GR levels in ovarian
cancer cells.
Conclusions: These results suggest that GR may be a potential target for BRCA1 in ovarian cancer progression.
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Ovarian cancer is the most lethal gynecological malig-
nancy in women worldwide [1]. To date, although the
exact cause of ovarian cancer remains largely unknown,
BRCA mutations are the main known hereditary factor
[2], and the risk of ovarian cancer conferred by BRCA
mutations can be regulated by both genetic and environ-
mental components [3]. Glucocorticoid action in cells is
mediated by the glucocorticoid receptor (GR), a member
of the superfamily of ligand-inducible transcription fac-
tors that exert a variety of physiological functions, such
as inflammation, autoimmune diseases, and cancer [4].
Recently, the glucocorticoid system has drawn consider-
able interest in the field of ovarian cancer therapy, with* Correspondence: leeda@ymail.com
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unless otherwise stated.studies involving, for instance, glucocorticoids-induced
chemotherapy resistance in ovarian cancer cells [5,6];
GR may be involved in the pathogenesis of ovarian cancer
via the regulation of apoptosis and aberrant cell migration
[7]. In addition, emerging evidence has suggested that: (i)
both genetic and environmental factors contribute to im-
paired GR function [8]; (ii) GR inactivation is a hallmark
for BRCA1-mutated breast cancer tissues [9]; and (iii) the
BRCA1-interacting protein NELF-B participates in GR-
mediated gene induction [10]. However, to date, little is
known about the effects of BRCA dysfunction on GR in
ovarian cancer. Therefore, insights into the complex
interrelationship between BRCA and GR might im-
prove our understanding of the basic molecular mechan-
ism of ovarian cancer. For this reason, the present study
was undertaken to investigate GR expression after BRCAd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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knockdown), and to provide novel insights into the regula-
tory mechanism of GR in ovarian cancer progression.Methods
Patients and tissue collection
This study was approved by the Institutional Review
Board at China Medical University. Serous ovarian can-
cer patients were enrolled between 2010 and 2012, and
all patients gave informed consent. Fresh tumor samples,
adjacent normal ovarian tissues, ascites, and blood sam-
ples were obtained at the time of primary surgery before
any chemotherapy or radiotherapy (28 pairs of BRCA1-
mutated or not, 23 pairs of BRCA2-mutated or not, and
22 pairs with hypermethylated BRCA1 promoter or not).
Hematoxylin and eosin staining of the samples for
histopathological diagnosis and grading were deter-
mined by three staff pathologists using the World
Health Organization criteria. All patients were screened
for BRCA1 and BRCA2 mutations by multiplex polymer-
ase chain reaction (PCR) with complete sequence analysis
as previously described [11]; their characteristics are given
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Figure 1 GR expression patterns in non-mutated and
BRCA1-mutated ovarian cancer. A, relative GR mRNA levels were
measured in 28 pairs of non-mutated and BRCA1-mutated ovarian
cancer and their adjacent normal tissue. Bar graphs show mean ± SD.
B, GR protein levels assessed by immunohistochemistry in 28 pairs of
non-mutated and BRCA1-mutated ovarian cancer and their adjacent
normal tissue. Intensity of the staining was scored by division into 10
arbitrary units based on the Mean Density (see details in Methods:
Immunohistochemistry).Cell culture and lentiviral transfection
Primary ovarian cancer cells were obtained from the
ascites of patients undergoing surgery for ovarian cancer
and cultured in RPMI 1640 with 10% fetal bovine
serum (Invitrogen, CA USA), using methods reported by
Szlosarek [12]. Human 293 T cells and wild-type SKOV3
ovarian carcinoma cells were maintained in DMEM with
10% fetal bovine serum (Invitrogen). Lentiviral vectors
expressing short hairpin RNAs (shRNAs) against BRCA1
(NM_007299) were obtained from GeneChem Co., Ltd
(Shanghai, China), and synthesized as follows: Forward:
5′-CCGGAACCTGTCTCCACAAAGTGTGCTCGAGC
ACACTTTGT GGAGACAGGTTTTTTTG-3′, and Re-
verse: 5′-AATTCAAAAAAACCTGT CTCCACAAAGT
GTGCTCGAGCACACTTTGTGGAGACAGGTT-3′. The
non-silencing shRNA sequence was used as a negative
control and synthesized as follows: forward, 5′-ccggTT
CTCCGAACGTGTCACGTctcgagACGTGACACGTTCG
GAGAAtttttg-3′, and reverse, 5′-aattcaaaaaTTCTCCGA
ACGTGTCACGTctcgagACGTGACACGTTCGGAGAA-
3′. For overexpression of BRCA1, the open reading
frame of BRCA1 (NM_007299) was cloned into the lenti-
viral vector GV287 (Ubi-MCS-3FLAG-SV40-EGFP; Gene-
Chem Co., Ltd). Transfections were performed using
polybrene and enhanced infection solution (GeneChem
Co., Ltd) according to the manufacturer’s recommended
protocol. The efficiency of BRCA1 knockdown and over-
expression was shown in Additional file 2 (supplementary
methods are shown in Additional file 3).Real-time quantitative PCR
Total RNA was extracted using Trizol reagents (Invitro-
gen) according to the manufacturer’s protocol. DNA con-
tamination was removed by adding DNase I (Invitrogen)
according to the manufacturer’s protocol. Total RNA was
then reverse-transcribed from 2 μg of RNA using the
PrimeScript RT Master Mix kit (TaKaRa, Dalian, China)
and amplified by SYBR Premix Ex TaqTM II (TaKaRa) in a
Roche LightCycler 2.0 instrument (Roche Diagnostics,
Mannheim, Germany). The specific primer sequences were
as follows: GR: 5′- TGTTTTGCTCCTGATCTGA -3′ (F)
and 5′- TCGGGGAATTCAATACTCA-3′ (R); BRCA1:
5′-GGCTATCCTCTCAGAGTGACATTT-3′ (F) and 5′-
GCTTTATCAGGTTATGTTGCATGG-3′ (R); GAPDH:
5′-AGGTGAAGGTCGGAGTCA-3′ (F) and 5′-GGTCAT
TGATGGCAACAA-3′(R). GAPDH mRNA was amplified
as an internal control for normalization of each sam-
ple. All samples were analyzed in triplicate using the
2–ΔΔCT method.
Immunohistochemistry
The standard SP kit (Zhongshan, Beijing, China) was used
for immunohistochemical staining. Briefly, serial 4-μm
sections were obtained from each paraffin-embedded tis-
sue block. Following deparaffinization and rehydration,
sections were subjected to microwave antigen retrieval.
The primary antibodies were rabbit polyclonal anti-GR
(1:100; Santa, Cruz Biotechnologies, USA) and rabbit
polyclonal anti-BRCA1 (1:100; Santa), and the sections
were incubated overnight at 4°C with this antibody. 3,3′-
diaminobenzidine was used as the chromogen. Nuclei
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dried and mounted. Negative controls were incubated
with phosphate-buffered saline instead of the antibody.
Immunostaining was evaluated by two independent pa-
thologists, who were blinded to the identity of the subject
groups. Area quantification was performed with a light
microscope at a magnification of 400× and analyzed using
Image-Pro Plus 6.0 (Media Cybernetics, USA). Intensity of
the staining was scored by division into 10 arbitrary
units based on the Mean Density: 0.00 to 0.05 = 0;
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Figure 2 GR expression patterns in ovarian cancer with hypermethyla
sites in the core promoter region of the BRCA1. Genomic coordinates are s
location of individual CpG dinucleotides (dashes), and BRCA1 RefSeq gene
line). The arrow indicates the direction of transcription. B, comparative ana
ovarian cancer and adjacent normal tissue. The circles correspond to the CpG
open circles, unmethylated. Ten individual clones were sequenced for each sa
from the measurements shown in Figure 2B. D, relative BRCA1 mRNA levels w
promoter, compared with their adjacent normal tissue. E, relative GR mRNA le
compared with their adjacent normal tissue. Each group, n = 22. Bar graphs shto 0.25 = 4; 0.25 to 0.30 = 5; 0.30 to 0.35 = 6; 0.35 to
0.40 = 7; 0.40 to 0.45 = 8; >0.45 = 9. Any boundary values
were classified as upper class.
Bisulfite sequencing for BRCA1 promoter
All the tissues were used for bisulfite sequencing from the
non-BRCA1-mutated cases. Genomic DNA extracted from
ovarian cancer and normal ovarian tissue with a TIANamp
Genomic DNA kit (Tiangen Biotech, Beijing, China) was
subjected to bisulfite conversion using the EZ DNA
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ted promoter-mediated BRCA1 inactivation. A, the location of CpG
hown, along with the primer-amplified fragments, GC percentage,
(exon 1 is shown as a blue box and the intron is shown as an arrowed
lysis of methylation patterns in the core promoter region of BRCA1 in
sites denoted by black dashes in Figure 2A. Closed circles, methylation;
mple. C, summary of the methylation levels of BRCA1 core promoter
ere measured in ovarian cancer with identified hypermethylated BRCA1
vels were measured in ovarian cancer with identified BRCA1 inactivation,
ow mean ± SD.
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efficiency was estimated to be at least 99.6%. It was then
amplified by nested PCR. After gel purification, cloning
and transformation into E. coli Competent Cells JM109
(TaKaRa), ten positive clones of each sample were sequen-
ced to ascertain the methylation patterns of each CpG
locus. The following primers were used for BRCA1 gene
(Accession number: NG_005905;) promoter: round I, F:
5′-TTGTAGTTTTTTTAAAGAGT-3′ and R: 5′-TACT
ACCTTTACCCAAAACAAAA-3′; round II, F: 5′-GTAG
TTTTTTTAAAGAGTTGTA-3′ and R: 5′-ACCTTTAC
CCAAAACAAAAA-3′. The conditions were as follows:
95°C for 2 min, 40 cycles of 30 s at 95°C, 30 s at 56°C and
45 s at 72°C, then 72°C for 7 min.
Statistical analysis
Regression analysis was used to examine the possible
relationship between GR and BRCA1 expression. The
data are presented as means ± SD. Statistical differences
in the data were evaluated by Student’s t-test or one-way
ANOVA as appropriate, and were considered significant



































Figure 3 Correlation between the expression levels of BRCA1 and GR
between the BRCA1 and GR mRNA levels in 40 non-BRCA1-mutated ovaria
showing the positive correlation between the expression levels of BRCA1 a
is 400×.Results
Differences in expression patterns of GR in non-mutated
and BRCA1-mutated ovarian cancer
Real-time PCR and immunohistochemical analysis showed
that there were no significant differences in the expression
of GR mRNA and protein between non-BRCA1-mutated
ovarian cancer and adjacent normal tissue (Figure 1A and B).
It is, however, interesting to note that BRCA1-mutated
ovarian cancer tissue showed dramatically reduced the
expression of GR compared to adjacent normal tissue
(Figure 1A and B). In contrast, expression levels of GR were
not affected by BRCA2 mutations (Additional file 4).
Hypermethylated BRCA1 promoter-mediated decreased
expression of BRCA1 is positively correlated with GR levels
In mammals, promoter methylation at CpG dinucleo-
tides is an important feature regulating gene expression
[13]. Consistent with this idea, we showed that ovarian
cancer tissue with a hypermethylated BRCA1 promoter
(Figure 2B and C) displayed decreased expression of
BRCA1 in comparison with adjacent normal tissue










in non-BRCA1-mutated ovarian cancer samples. A, correlation
n cancer tissues. B, examples of immunohistochemical staining













































































































Figure 4 Effects of BRCA1 on GR expression. A–D, relative GR
mRNA levels after the overexpression or knockdown of BRCA1 in
293 T cells, wild-type SKOV3 ovarian cancer cells, and primary non-
mutated and BRCA1-mutated ovarian cancer cells (repeated 12 times
for each group). Bar graphs show mean ± SD. Sh, short hairpin RNAs;
Op, overexpression.
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the low levels of BRCA1 appeared to be mediated by pro-
moter hypermethylation, making this an appropriate
model to investigate the physiological relationship be-
tween BRCA1 and GR. Notably, the expression levels of
GR decreased markedly (Figure 2E), along with hyper-
methylated promoter-mediated BRCA1 deficiency in
ovarian cancer.
BRCA1 is positively correlated with GR expression in
non-BRCA1-mutated ovarian cancer samples
Of particular interest and potential clinical relevance,
the relationship between BRCA1 and GR expression was
studied in 40 non-BRCA1-mutated ovarian cancer speci-
mens. Our results showed that there was a significant
positive association between BRCA1 and GR protein
expression (Figure 3A and B). Notably, as shown in
Figure 3B, increased GR levels were mainly located in
the cytoplasm, along with the increased expression of
BRCA1 in ovarian cancer tissues.
BRCA1 can regulate GR expression in ovarian cancer cells
To confirm the role of BRCA1 in the regulation of GR,
the effects of overexpression or knockdown of BRCA1
were observed in 293 T cells, the human ovarian carcin-
oma cell line SKOV3, and primary ovarian cancer cells
with identified BRCA1 mutations or those which were
non-mutated. The results indicated that there were no
significant changes in the expression of GR after over-
expression or knockdown of BRCA1 in 293 T cells
(Figure 4A). Interestingly, we observed that overexpression
of BRCA1 was an effective way to induce an increase in GR
levels in SKOV3 cells, primary non-mutated and BRCA1-
mutated ovarian cancer cells (Figure 4B-D). BRCA1 knock-
down effectively inhibited the expression of GR in SKOV3
cells and primary non-BRCA1-mutated ovarian cancer cells
(Figure 4B and C). GR levels were not sensitive to the
BRCA1 knockdown in primary BRCA1-mutated ovarian
cancer cells (Figure 4D).
Discussion
In this study, we report for the first time an association
between BRCA1 and GR status in ovarian cancer: (i) the
BRCA1 inactivation group showed dramatically decreased
expression of GR compared with adjacent normal tissue;
(ii) there was a positive correlation between BRCA1 and
GR expression in human ovarian cancer specimens; (iii)
BRCA1 knockdown was effective at inhibiting GR expres-
sion, and overexpression of BRCA1 induces an increase in
GR levels in ovarian cancer cells. These results suggest
that GR may be a potential target for BRCA1 in ovarian
cancer. However, the regulatory effects of BRCA1 on GR
were only observed in ovarian cancer cells; 293 T cells
were insensitive to the knockdown or overexpression ofBRCA1. In addition, it is noteworthy that increased GR
levels were mainly located in the cytoplasm nor the nuclei,
along with the increased expression of BRCA1. Therefore,
it appears that BRCA1 may be involved in the inhibition
of GR transfer to the nucleus, which is consistent with
previous findings [9]. Notably, a growing body of data
suggests that there is extensive crosstalk among BRCA1
signaling pathways and several hormone receptors. For ex-
ample, both the insulin-like growth factor 1 receptor [3]
and epidermal growth factor receptor [14] are down-
stream targets for BRCA1; BRCA1 inhibits the trans-
criptional activity of progesterone receptor (PR) in the
PR-positive breast cancer cell line T47D [15]; and ER-alpha
activity can be suppressed by BRCA1 through regulating
the acetylation vs. ubiquitination [16]. However, there have
been few reports about the interactions between BRCA1
and GR in ovarian cancer. It is interesting to note that loss
of function of the tumor suppressor gene BRCA1 plays an
important role in promoting cell proliferation and survival
[17,18]. The mechanism may involve: 1) inducing insulin-
like growth factor 1 expression [3,19] in an estrogen re-
ceptor α-dependent manner [19,20], and 2) stimulating
PR activity by facilitating progesterone binding to the
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an anti-proliferative effect on various cells [22]. Therefore,
the discovery of BRCA1- inactivation mediated GR repres-
sion will stimulate new interest in BRCA1-related cellular
proliferation. To date, it is not fully understood how
BRCA1 activates GR transcription at the molecular level.
However, some insight was gained by a recent study which
reported that BRCA1 can regulate GR activity through GR
phosphorylation on Ser211 by modulating MAPK p38 in
MCF-7 and MDA-MB-231 cell lines [9].
Conclusions
Our results indicate that BRCA1 may be a potential
regulator of GR in ovarian cancer cells. Based on these
findings, there are some interesting issues that need to be
considered in future studies; for example, how BRCA1
affects GR transcription and whether other factors could
cooperate with BRCA1 in controlling GR expression. Also,
the complex interactions between BRCA1 and GR signal-
ing pathways need to be clarified. All of this may improve
our understanding of the basic molecular mechanism of
BRCA1-related ovarian cancer.
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